Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).
In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.
Further, the company has supply and distribution agreement with BiommS. A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India.
MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 24 | -0.01 Increased by +50.00% | 0.01 Decreased by -200.00% |
| May 8, 24 | 0.04 Increased by +200.00% | 0.03 Increased by +33.33% |
| Feb 27, 24 | 0.00 Increased by +106.14% | 0.01 Decreased by -57.00% |
| Nov 7, 23 | 0.01 Increased by +116.67% | -0.02 Increased by +150.00% |
| Aug 7, 23 | -0.02 Increased by +81.82% | -0.04 Increased by +50.00% |
| May 9, 23 | -0.04 Increased by +60.00% | -0.05 Increased by +20.00% |
| Feb 22, 23 | -0.07 Increased by +36.36% | -0.06 Decreased by -16.67% |
| Nov 8, 22 | -0.06 Decreased by -200.00% | -0.09 Increased by +33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 19.73 M Decreased by -61.51% | 11.55 M Increased by +571.12% | Increased by +58.55% Increased by +1.64 K% |
| Jun 30, 24 | 72.39 M Increased by +48.91% | -2.01 M Increased by +61.75% | Decreased by -2.78% Increased by +74.31% |
| Mar 31, 24 | 66.26 M Increased by +63.10% | 10.63 M Increased by +166.37% | Increased by +16.04% Increased by +140.69% |
| Dec 31, 23 | 58.47 M Increased by +62.16% | 1.40 M Increased by +106.03% | Increased by +2.40% Increased by +103.72% |
| Sep 30, 23 | 51.25 M Increased by +56.14% | 1.72 M Increased by +108.73% | Increased by +3.36% Increased by +105.59% |
| Jun 30, 23 | 48.61 M Increased by +157.28% | -5.26 M Increased by +83.27% | Decreased by -10.83% Increased by +93.50% |
| Mar 31, 23 | 40.63 M Increased by +238.78% | -16.02 M Increased by +48.53% | Decreased by -39.42% Increased by +84.81% |
| Dec 31, 22 | 36.06 M Increased by +188.13% | -23.23 M Increased by +17.20% | Decreased by -64.43% Increased by +71.26% |